09:00 – 09:15
Welcome & Opening Address
Michael Ison
DMID/NIAID/NIH, Rockville, MD, USA

09:15 – 10:00
Opening Keynote
Chair: Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA
The Development of Small Molecules for the Treatment of Respiratory Viral Illnesses: Important Lessons From A Burgeoning New Era
Richard Whitley
University of Alabama, Birmingham, AL, USA

SESSION 1
10:00 – 11:30
PRECLINICAL – VIRAL TARGETS
Co-Chairs: Lieve Naesens, Rega Institute, Leuven, Belgium and Hui-Ling Yen, University of Hong Kong, Hong Kong SAR, China

10:05 – 10:30
Insights from Coronavirus Replication in Developing Antivirals
Mark Denison
Vanderbilt University Medical Center, Nashville, TN, USA

10:30 – 10:55
A Molecularly Modified Lectin for the Prevention and Treatment of Coronaviruses and Influenza
David Markovitz
University of Michigan, Ann Arbor, MI, USA

10:55 – 11:20
Non-nucleoside RSV Polymerase Inhibitor
Richard Plemper
Georgia State University, Atlanta, GA, USA

11:20 – 11:30
Panel Discussion

SESSION 2
11:45 – 13:15
PRECLINICAL – HOST-DIRECTED ANTIVIRAL THERAPEUTICS
Co-Chairs: Bin Cao, Capital Medical University, Beijing, China and Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France

11:45 – 12:15
Harnessing Interferon Responses as Potential Broad Spectrum Respiratory Antiviral Treatments
Evangelos Andreakos
Biomedical Research Foundation, Academy of Athens, Greece

12:15 – 12:40
Towards a Novel Host-targeted Anti-infective Strategy for COVID-19 and Other Acute Respiratory Viral Diseases
Stephan Ludwig
Westfälische-Wilhelms-University, Münster, Germany
12:40 – 13:05
Combined Inhibition of Viral and Host Factors to Maximize Antiviral Activity
Sara Cherry
University of Pennsylvania, Philadelphia, PA, USA

13:05 – 13:15
Panel Discussion

13:15 – 14:15 Lunch and Poster Viewing

ORAL ABSTRACT SESSION 1 – PRECLINICAL DEVELOPMENT
Co-Chairs: Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA and Rich Whitley, University of Alabama, Birmingham, AL, USA

14:15 – 14:30
Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor (AASU0006)
Andreas Jekle
Aligos Therapeutics, South San Francisco, CA, USA

14:30 – 14:45
CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B (AASU0009)
James Levin
Cidara Therapeutics, San Diego, CA, USA

14:45 – 15:00
A Pseudovirus-Based System for Mapping the Antigenic Effects of Thousands of Mutations in SARS-CoV-2 Spike (AASU0045)
Bernadeta Dadonaite
Fred Hutchinson Cancer Center, Seattle, WA, USA

15:00 – 15:15
Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections (AASU0039)
Hella Kohlhof
Immunic AG, Gräfelfing, Germany

15:15 – 15:30
Inhaled Muco-Trapping Monoclonal Antibody for Effective Therapy Against Respiratory Syncytial Virus Infections in Lambs (AASU0047)
Sam Lai
University of North Carolina, Chapel Hill, NC, USA

15:30 – 15:45
Live Imaging of Airway Epithelium Reveals Mucociliary Clearance Modulates Spread of SARS-CoV-2 (AASU0034)
Mark Becker
Northwestern University, Chicago, IL, USA

15:45 – 16:05 Coffee Break
SESSION 4
16:05 – 17:45

CLINICAL TRIAL DESIGN ISSUES/
HUMAN CHALLENGE/OMICS
Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and Cameron Wolfe, Duke University Medical Center, NC, USA

16:10 – 16:25
Randomized, Placebo Control Trials – Lessons from ACTT
John Beigel
NIAID/NIH, Rockville, MD, USA

16:25 – 16:40
The RECOVERY Trial: Lessons and Legacy
Peter Horby
University of Oxford, Oxford, UK

16:40 – 16:55
The SARS-CoV-2 Human Challenge Model
Chris Chiu
Imperial College, London, UK

16:55 – 17:10
Use of Omics Approaches in the Context of Clinical Trials:
Development of Improved Influenza Interventions
Teresa Aydillo
Icahn School of Medicine at Mount Sinai, New York, NY, USA

17:10 – 17:25
Fully Remote Trials
Caleb Skipper
University of Minnesota, Minneapolis, MN, USA

17:25 – 17:45
Panel Discussion

THURSDAY
PROGRAMME
4 MAY 2023

SESSION 5
8:30 – 10:45

UPDATES ON CLINICAL TRIALS
Co-Chairs: David Hui, The Chinese University of Hong Kong, Hong Kong SAR, China and Helen Chu, University of Washington, Seattle, WA, USA

08:35 – 09:05
Keynote Talk
REMAP-CAP: Preparing for the Pandemic and Translating the Network into Seasonal Threats
Srinivas Murthy
BC Children’s Hospital, Vancouver, Canada

09:05 – 09:25
Clinical Trials of Severe Viral Pneumonia
Bin Cao
China-Japan Friendship Hospital, Beijing, China
09:25 – 09:45
Monoclonal Antibodies – Current State of the Art and Future Directions
James Crowe
Vanderbilt University Medical Center, Nashville, TN, USA

09:45 – 10:05
Antiviral Respiratory Viral Therapies for Children
Janet Englund
Seattle Children's Hospital, Seattle, WA, USA

10:05 – 10:25
Update on Clinical Trials: Small Molecules and Antibodies for RSV Management
Angela Branche
University of Rochester Medical Center, Rochester, NY, USA

10:25 – 10:45
Panel Discussion

10:45 – 11:05  Coffee Break

SESSION 6
11:05 – 12:35

ORAL ABSTRACT SESSION 2 – ANTIVIRALS, MONOCLONAL ANTIBODIES AND COMBINATIONS
Co-Chairs: Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan and Tim Uyeki, CDC, Atlanta, GA, USA

11:05 – 11:20
First-in-Human Study of CC-42344, a Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor (AASU0024)
Sam Lee
Cocrystal Pharma Inc., Bothell, WA, USA

11:20 – 11:35
Safety and Efficacy Results from Phase 1 and 2a H1N1 Challenge Trials Using an Anti-Type A and B Influenza Immunotherapeutic that is also Synergistic with Oseltamivir in Mice (AASU0041)
Thomas Luke
SAB Biotherapeutics, Sioux Falls, SD, USA

11:35 – 11:50
CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates a High Barrier to Resistance and Retains Potent Activity Against Neuraminidase Inhibitor-Resistant Influenza A and B (AASU0008)
Simon Döhrmann
Cidara Therapeutics, San Diego, CA, USA

11:50 – 12:05
Akimasa Fukushi
Shionogi & Co., Ltd, Osaka, Japan

12:05 – 12:20
Clinical Trials of Inhaled Interferon Beta-1a (SNG001) in COVID-19 Patients in the Home and Hospital Settings (AASU0014)
Phillip Monk
Synairgen Research Ltd, Southampton, Hants, UK
Ensitrelvir for Symptomatic and Mild Symptoms Only: COVID-19 Patients in Phase 2b/3 Part (AASU0010)
Genki Ichihashi
Shionogi & Co., Ltd, Osaka, Japan

Combination Therapy to Treat Respiratory Infections: Ready for Primetime?

Introduction
Michael Ison
DMID/NIAID/NIH, Rockville, MD, USA

The Challenges of Monotherapy – a View from the Immunocompromised Host
Michael Boeckh
Fred Hutchinson Cancer Center, Seattle, WA, USA

Combination Antiviral Therapy for RVIs: Update on Clinical Progress
Frederick Hayden
University of Virginia School of Medicine, Charlottesville, VA, USA

Antivirals plus Immune Modulators
John Beigel
NIAID/NIH, Rockville, MD, USA

Panel Discussion

CLINICAL TRIAL AND REGULATORY ISSUES
Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA

Regulatory Framework for Moving from EUA to FDA Approval for Antiviral Products
Stephanie Troy
US FDA, Silver Spring, MD, USA

Clinical Trial Endpoints for Approval of Antiviral Therapeutics
Marco Cavaleri
EMA, Amsterdam, The Netherlands

Combination Therapy
Mariana Baz
CHU de Québec-Université Laval, Québec, Canada
15:20 – 15:40
The Path Forward for the Treatment of Hospitalized Influenza Patients: Host-Targeted Therapeutics
Kimberly Armstrong
BARDA, Washington DC, USA

15:40 – 15:50
Panel Discussion

15:50 – 16:10  Coffee Break & Poster viewing

TREATMENT UPDATES & ORAL ABSTRACT SESSION 3
Co-Chairs: Kimberly Armstrong, Biomedical Advanced Research and Development Authority (BARDA), Washington DC, USA and Shikha Garg, CDC, Atlanta, GA, USA

16:10 – 16:55
State of the Art of COVID-19 Therapy
Cameron Wolfe
Duke University Medical Center, Durham, NC, USA

16:55 – 17:10
Comparison of the Effectiveness of Baloxavir Marboxil and Oseltamivir in Reducing Household Transmission of Influenza (AASU0004)
Takamichi Baba
Shionogi & Co., Ltd, Osaka, Japan

17:10 – 17:25
Heterogeneity of Influenza Infection Severity at Hospital Admission Significantly Confounds Analysis of Antiviral Effectiveness on Reducing Hospital Length of Stay (AASU0038)
Aleda Leis
University of Michigan, Ann Arbor, MI, USA

17:25 – 17:40
Pharmacokinetics of an Extended Half-Life Monoclonal Antibody Against COVID-19 in Hematopoietic Stem Cell Transplant Recipients (AASU0007)
Jim Boonyaratanakornkit
Fred Hutchinson Cancer Center, Seattle, WA, USA

17:40 – 17:55
Trial in Progress: a Phase I/III, Randomised Controlled Pre-exposure Prophylaxis Study of the Anti-SARS-CoV-2 Antibody AZD3152 (SUPERNOVA) (AASU0016)
Taylor Cohen
AstraZeneca, Gaithersburg, MD, USA

17:55 – 18:10
Meta-Analysis and Validation of OMICs Data from COVID-19 Patient Samples Reveal Auranofin as a Promising Therapeutic Agent (AASU0046)
Shashank Tripathi
Indian Institute of Science, Bengaluru, Karnataka, India

18:10 – 19:10
Poster Reception and Poster viewing
# Friday Programme

## 08:30 – 08:40
**Introduction to Roberts/Tisdale Lectureship**
Maria Zambon  
UK Health Security Agency (UKHSA), London, UK / Chair of ISIRV

## 08:40 – 09:25
**Keynote Talk – Roberts/Tisdale Lectureship**
Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK  
**Resistance to Antivirals Targeting Respiratory Viruses: When Does it Matter?**
Wendy Barclay  
Imperial College, London, UK

## 09:25 – 10:55
**THE RIGHT DRUG FOR THE RIGHT PATIENT: OPTIMIZING ANTIVIRAL TREATMENT**
Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK

### 09:30 – 09:55
**Role of Genomic Surveillance in Tracking Emergence of Resistance Over Time**
Adam Lauring  
University of Michigan, Ann Arbor, MI, USA

### 09:55 – 10:20
**Understanding Infection and Immunity of SARS-CoV-2: from Diagnostics to Therapies**
Lisa Ng  
A*STAR Infectious Diseases Labs, Singapore

### 10:20 – 10:45
**Role of Misinformation and Erosion of Social Trust in Response to Pandemics**
Rachel Moran  
University of Washington, Seattle, WA, USA

### 10:45 – 10:55
**Panel Discussion**

## 10:55 – 11:15  Coffee Break

## 11:15 – 12:45
**ORAL ABSTRACT SESSION 4 – SURVEILLANCE & ANTIVIRAL RESISTANCE**
Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and Arnold Monto, University of Michigan, Ann Arbor, MI, USA

### 11:15 – 11:30
**Implementation of Cell Culture-Based Assay IRINA for Baloxavir Susceptibility Monitoring, 2022-23 Influenza Season** (AASU0018)
Mira Patel  
CDC, Atlanta, GA, USA
11:30 – 11:45
ViralVar: A Web Tool for Multilevel Visualization of SARS-CoV-2 Genomes (AASU0020)
Arghavan Alisoltani
Northwestern University, Chicago, IL, USA

11:45 – 12:00
Utilization of Whole Genome Sequencing to Augment Traditional Contact Tracing for a University SARS-CoV-2 Outbreak (AASU0044)
Cameron Wolfe
Duke University Medical Center, Durham, NC, USA

12:00 – 12:15
Whole Genome Sequencing Exploring Evolution Associated with the Combined Effect of Oseltamivir and Favipiravir on Influenza Virus (AASU0011)
Shengrui Mu
China-Japan Friendship Hospital, Beijing, China

12:15 – 12:30
Intra-host Population Dynamics of a SARS-CoV-2 Delta-Omicron Superinfection in an Immunocompromised Pediatric Patient (AASU0021)
Lacy Simons
Northwestern University, Chicago, IL, USA

12:30 – 12:45
Altered RSV Population Structures in Adult Populations Following COVID-19 Mitigation Strategies (AASU0036)
Estefany Rios Guzman
Northwestern University, Chicago, IL, USA

12:45 – 13:45 Lunch

13:45 – 14:50
ACCESS TO CARE/GLOBAL ROLLOUT
Co-Chairs: Helen Chu, University of Washington, Seattle, WA, USA and Janet Englund, Seattle Children’s Hospital, Seattle, WA, USA

13:50 – 14:15
Global Public Health Security and Justice for Vaccines and Therapeutics in the COVID-19 Pandemic
Sylvie Briand
WHO, Geneva, Switzerland

14:15 – 14:40
Enabling Access to Medical Countermeasures by Underserved Populations
Meghan Pennini
HHS, Washington, DC, USA

14:40 – 14:50
Panel Discussion

14:50 – 15:00
Summary & Close